Frank J. Hsu - 23 Aug 2023 Form 4 Insider Report for Apexigen, Inc.

Role
Chief Medical Officer
Signature
/s/ Francis Sarena, by power of attorney
Issuer symbol
N/A
Transactions as of
23 Aug 2023
Net transactions value
$0
Form type
4
Filing time
25 Aug 2023, 19:10:45 UTC
Previous filing
23 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APGN Common Stock Disposed to Issuer -16,354 -100% 0 23 Aug 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APGN Employee Stock Option (right to buy) Disposed to Issuer -224,872 -100% 0 23 Aug 2023 Common Stock 224,872 $4.79 Direct F2
transaction APGN Employee Stock Option (right to buy) Disposed to Issuer -27,000 -100% 0 23 Aug 2023 Common Stock 27,000 $2.46 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Frank J. Hsu is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), each share of Issuer common stock was exchanged for 0.1725 shares of Pyxis common stock and rounded down to the nearest whole share.
F2 One-fourth of the shares subject to the option vested on August 30, 2022 and 1/36th of the remaining shares vest monthly thereafter. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 38,789 shares of Pyxis common stock at an exercise price of $27.77 per share.
F3 The shares subject to the option vest in 48 equal monthly installments beginning on February 1, 2022. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 4,656 shares of Pyxis common stock at an exercise price of $14.27 per share.